Abstract
Fingolimod is approved for the treatment of relapsing-remitting multiple sclerosis (MS), and evidence suggests that it has neuroprotective effects. The recent INFORMS phase III trial in primary progressive MS demonstrated no beneficial effects of fingolimod on disability progression or whole-brain atrophy, but provides important information for future therapeutic development.
Original language | English (US) |
---|---|
Pages (from-to) | 253-254 |
Number of pages | 2 |
Journal | Nature Reviews Neurology |
Volume | 12 |
Issue number | 5 |
DOIs | |
State | Published - May 1 2016 |
Externally published | Yes |
Bibliographical note
Funding Information:A.L.S. is supported by a National Multiple Sclerosis Society Sylvia Lawry Physician Fellowship Award (FP 17117-A-2).
Publisher Copyright:
© 2016 Macmillan Publishers Limited. All rights reserved.